• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Stony Hill Advisory Board Includes a Former Pfizer Director and More

December 13, 2017

 (Photo Credit - Montgomery County Planning Commission)


While many people know that Stony Hill Corp. (OTC:STNY) was founded by Damian Marley, the company's advisory board doesn't get nearly enough attention. While we covered the appointment of Dr. James Mulé as its first member back in May, a quick look at the company's website shows some new additions. 


Advisory Board vs. Board of Directors


When growing companies need guidance, they often look to their trusted advisory board. Different than a company's Board of Directors, a company's advisory board is a committee of hand-selected individuals with substantial experience in their fields. 


Stony Hill's advisory board is comprised of individuals with some incredible and noteworthy credentials, including the former business unit Chief Medical Officer and senior director of oncology research and development with the pharmaceutical giant Pfizer Inc. (NYSE:PFE)


Dr. Raymond Urbanski


According to Stony Hill's website, "Dr. Raymond W. Urbanski, M.D., Ph.D. has been Chief Medical Officer at GT Biopharma, Inc. since September 2017. Dr. Urbanski oversees the development of key products in GT Biopharma’s product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies. Previously, he served as the Chief Medical Officer of MannKind Corp. from August 10, 2015 until September 29, 2017 and its Corporate Vice President until September 2017. Dr. Urbanski led MannKind’s overall drug development activities and is a member of the Executive Leadership Team. Previously, he served as Chief Medical Officer and Senior Director of oncology research and development at Pfizer Inc. (PFE). Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products. He served as the Vice President and Medical Head of the Established Products Business Unit at Pfizer since 2008 which he built into a global business. From 2004 to 2008, he held various positions in the Pfizer Global Pharmaceutics Group. He has extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor and tremelimumab. In addition to his role with Pfizer, he served as Chief Medical Officer of Mylan Inc., and Senior Director of US Medical Affairs for Aventis. He served as the Chief Medical Officer at Cymabay Therapeutics, Inc. (alternate name, Metabolex, Inc.) since October 2011. He served as the Vice President for Research and Development at Suntory Pharmaceutical, Inc. from 2001 to 2004 and its CMO. He held various positions at Aventis and AstraZeneca from 1998 to 2001. Dr. Urbanski received his Ph.D. in pharmacology and Toxicology and his M.D. from the University of Medicine and Dentistry of New Jersey."


James H. Bailey


James Bailey is the Founder and Managing General Partner of Velos Partners a technology and consumer fund with offices in Los Angeles and Singapore. James is also the Founder or Bailey Ventures, a cannabis investment company with stakes in industry leading brands like Pax, Eaze, High Times, Bloom Farms and Zynerba. James previously worked at Accel Partnerss, Highland Capital, TA Associates and Upfront Ventures.


Professor Oded Shoseyov


According to Stony Hill's website, Professor Oded Shoseyov "is a Co-Founder of SP Nano Ltd. and serves as its Scientific Advisor. Prof. Shoseyov is the Scientific Founder of CBD Technologies., FuturaGene, Melodea and Bondex. He founded Collplant Holdings Ltd. in 2004 and has been its Chief Scientist Officer since August 2008. He serves as the Chief Scientist at CBD Technologies Ltd. Prof. Shoseyov He is a Founder of Fulcrum SP Ltd. Prof. Shoseyov is a Faculty Member of the Institute of Plant Science and Genetics in Agriculture and the Otto Warburg Center for Agricultural Biotechnology at the Faculty of Agriculture, Food and Environmental Quality Sciences of the Hebrew University of Jerusalem. His main field of research is plant molecular biology and biotechnology. He has extensive experience with genetic engineering of plants, protein engineering and nano-biotechnology. He serves as a Member of Advisory Board at EQUI-nom Ltd. Prof. Shoseyov serves as a Member of Scientific Advisory Board of FuturaGene Plc (now known as FuturaGene, LTD.). He served as a Director of Collplant Holdings Ltd. from May 20, 2010 to October 2016. He is an invited Speaker at many scientific conferences and has published extensively. He is the Inventor Or Co-inventor of more than 14 patents, 9 of which relate directly to CBD Technologies business. He has authored or co-authored more than 160 scientific publications and is the inventor or co-inventor of 42 patents. He has received numerous awards and appointments for his research in agricultural biotechnology. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002 and the 1999 Kay Award for Innovative and Applied Research. He received his B.S. with Excellence in 1981, his M.S. with Excellence in 1983 and his Ph.D. summa cum laude in 1988 from the Hebrew University of Jerusalem."

Dr. James Mulé


According to Stony Hill's website, "Dr. Mulé is Associate Center Director, the U.S. Sen ator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunoth erapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. He has published nearly 200 articles. Dr. Mulé serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, KB Capital Management, among others). Dr. Mulé remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Dr. Mulé also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). Dr. Mulé received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal post-graduate training at the Surgery Branch , Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Dr. Mulé moved to Palo Al to, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endo wed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine."




We'll be watching closely to see how these industry veterans help Stony Hill on it's climb to industry leadership. To stay up to date with important developments in the cannabis industry, be sure to subscribe to one or more of our free email newsletters. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!



Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.